首頁 > 市場調查報告書 > 製藥 > 非專利藥 > 學名藥產業：全球產業指南

聯絡我們?

市場調查報告書

學名藥產業：全球產業指南

Generics: Global Industry Guide

出版商	Datamonitor
出版日期	2011年09月	商品編碼	217384
內容資訊	英文 Pages: 262
價格	US $ 1495 PDF by E-mail (Single user license) US $ 3738 PDF by E-mail (Global license)

簡介
目錄
相關商品

學名藥產業：全球產業指南 是由出版商Datamonitor在2011年09月所出版的。這份英文市場調查報告書包含Pages: 262 價格從美金1495起跳。

簡介

本報告針對全球學名藥產業提供地區/國家分類市場規模、五力分析、主要企業、市場預測、企業檔案分析，目錄介紹如下。

Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the Generics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.

Scope of the Report

Contains an executive summary and data on value, volume and segmentation
Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies
Incorporates in-depth five forces competitive environment analysis and scorecards
Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).
Includes a five-year forecast of the industry

Highlights

The global generics market grew by 6.9% in 2010 to reach a value of $169,078.3 million.
In 2015, the global generics market is forecast to have a value of $246,258.4 million, an increase of 45.6% since 2010.
The global generics market grew by 1.4% in 2010 to reach a volume of 74 % of total pharma volume.
In 2015, the global generics market is forecast to have a volume of 79.8 % of total pharma volume, an increase of 7.8% since 2010.
Americas accounts for 48.7% of the global generics market value.

Why you should buy this report

Spot future trends and developments
Inform your business decisions
Add weight to presentations and marketing materials
Save time carrying out entry-level research

Market Definition

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices. Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume. All currency conversions were calculated at constant average annual 2010 exchange rates.

ABOUT DATAMONITOR

EXECUTIVE SUMMARY

INTRODUCTION

What is this report about?
Who is the target reader?
Definitions

GLOBAL GENERICS

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts

GENERICS IN ASIA-PACIFIC

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts

GENERICS IN EUROPE

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts

GENERICS IN FRANCE

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

GENERICS IN GERMANY

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

GENERICS IN ITALY

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

GENERICS IN JAPAN

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

GENERICS IN BELGIUM

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

GENERICS IN CANADA

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

GENERICS IN CHINA

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

GENERICS IN THE NETHERLANDS

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

GENERICS IN SPAIN

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

GENERICS IN THE UNITED KINGDOM

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

GENERICS IN THE UNITED STATES

Market overview
Market value
Market volume
Market segmentation
Five forces analysis
Market forecasts
Macroeconomic indicators

COMPANY PROFILES

Bayer AG
Mylan Inc
Novartis AG
Teva Pharmaceutical Industries Limited

APPENDIX

Data Research Methodology

LIST OF TABLES

Table 1: Global generics market value: $ million, 2006-10
Table 2: Global generics market volume: % of total pharma volume, 2006-10
Table 3: Global generics market segmentation: % share, by value, 2010
Table 4: Global generics market value forecast: $ million, 2010-15
Table 5: Global generics market volume forecast: % of total pharma volume, 2010-15
Table 6: Asia-Pacific generics market value: $ million, 2006-10
Table 7: Asia-Pacific generics market volume: % of total pharma volume, 2006-10
Table 8: Asia-Pacific generics market segmentation: % share, by value, 2010
Table 9: Asia-Pacific generics market value forecast: $ million, 2010-15
Table 10: Asia-Pacific generics market volume forecast: % of total pharma volume, 2010-15
Table 11: Europe generics market value: $ million, 2006-10
Table 12: Europe generics market volume: % of total pharma volume, 2006-10
Table 13: Europe generics market segmentation: % share, by value, 2010
Table 14: Europe generics market value forecast: $ million, 2010-15
Table 15: Europe generics market volume forecast: % of total pharma volume, 2010-15
Table 16: France generics market value: $ million, 2006-10
Table 17: France generics market volume: % of total pharma volume, 2006-10
Table 18: France generics market segmentation: % share, by value, 2010
Table 19: France generics market value forecast: $ million, 2010-15
Table 20: France generics market volume forecast: % of total pharma volume, 2010-15
Table 21: France size of population (million), 2006-10
Table 22: France gdp (constant 2000 prices, $ billion), 2006-10
Table 23: France gdp (current prices, $ billion), 2006-10
Table 24: France inflation, 2006-10
Table 25: France consumer price index (absolute), 2006-10
Table 26: France exchange rate, 2006-10
Table 27: Germany generics market value: $ million, 2006-10
Table 28: Germany generics market volume: % of total pharma volume, 2006-10
Table 29: Germany generics market segmentation: % share, by value, 2010
Table 30: Germany generics market value forecast: $ million, 2010-15
Table 31: Germany generics market volume forecast: % of total pharma volume, 2010-15
Table 32: Germany size of population (million), 2006-10
Table 33: Germany gdp (constant 2000 prices, $ billion), 2006-10
Table 34: Germany gdp (current prices, $ billion), 2006-10
Table 35: Germany inflation, 2006-10
Table 36: Germany consumer price index (absolute), 2006-10
Table 37: Germany exchange rate, 2006-10
Table 38: Italy generics market value: $ million, 2006-10
Table 39: Italy generics market volume: % of total pharma volume, 2006-10
Table 40: Italy generics market segmentation: % share, by value, 2010
Table 41: Italy generics market value forecast: $ million, 2010-15
Table 42: Italy generics market volume forecast: % of total pharma volume, 2010-15
Table 43: Italy size of population (million), 2006-10
Table 44: Italy gdp (constant 2000 prices, $ billion), 2006-10
Table 45: Italy gdp (current prices, $ billion), 2006-10
Table 46: Italy inflation, 2006-10
Table 47: Italy consumer price index (absolute), 2006-10
Table 48: Italy exchange rate, 2006-10
Table 49: Japan generics market value: $ million, 2006-10
Table 50: Japan generics market volume: % of total pharma volume, 2006-10
Table 51: Japan generics market segmentation: % share, by value, 2010
Table 52: Japan generics market value forecast: $ million, 2010-15
Table 53: Japan generics market volume forecast: % of total pharma volume, 2010-15
Table 54: Japan size of population (million), 2006-10
Table 55: Japan gdp (constant 2000 prices, $ billion), 2006-10
Table 56: Japan gdp (current prices, $ billion), 2006-10
Table 57: Japan inflation, 2006-10
Table 58: Japan consumer price index (absolute), 2006-10
Table 59: Japan exchange rate, 2006-10
Table 60: Belgium generics market value: $ million, 2006-10
Table 61: Belgium generics market volume: % of total pharma volume, 2006-10
Table 62: Belgium generics market segmentation: % share, by value, 2010
Table 63: Belgium generics market value forecast: $ million, 2010-15
Table 64: Belgium generics market volume forecast: % of total pharma volume, 2010-15
Table 65: Belgium size of population (million), 2006-10
Table 66: Belgium gdp (constant 2000 prices, $ billion), 2006-10
Table 67: Belgium gdp (current prices, $ billion), 2006-10
Table 68: Belgium inflation, 2006-10
Table 69: Belgium consumer price index (absolute), 2006-10
Table 70: Belgium exchange rate, 2006-10
Table 71: Canada generics market value: $ million, 2006-10
Table 72: Canada generics market volume: % of total pharma volume, 2006-10
Table 73: Canada generics market segmentation: % share, by value, 2010
Table 74: Canada generics market value forecast: $ million, 2010-15
Table 75: Canada generics market volume forecast: % of total pharma volume, 2010-15
Table 76: Canada size of population (million), 2006-10
Table 77: Canada gdp (constant 2000 prices, $ billion), 2006-10
Table 78: Canada gdp (current prices, $ billion), 2006-10
Table 79: Canada inflation, 2006-10
Table 80: Canada consumer price index (absolute), 2006-10
Table 81: Canada exchange rate, 2006-10
Table 82: China generics market value: $ million, 2006-10
Table 83: China generics market volume: % of total pharma volume, 2006-10
Table 84: China generics market segmentation: % share, by value, 2010
Table 85: China generics market value forecast: $ million, 2010-15
Table 86: China generics market volume forecast: % of total pharma volume, 2010-15
Table 87: China size of population (million), 2006-10
Table 88: China gdp (constant 2000 prices, $ billion), 2006-10
Table 89: China gdp (current prices, $ billion), 2006-10
Table 90: China inflation, 2006-10
Table 91: China consumer price index (absolute), 2006-10
Table 92: China exchange rate, 2006-10
Table 93: Netherlands generics market value: $ million, 2006-10
Table 94: Netherlands generics market volume: % of total pharma volume, 2006-10
Table 95: Netherlands generics market segmentation: % share, by value, 2010
Table 96: Netherlands generics market value forecast: $ million, 2010-15
Table 97: Netherlands generics market volume forecast: % of total pharma volume, 2010-15
Table 98: Netherlands size of population (million), 2006-10
Table 99: Netherlands gdp (constant 2000 prices, $ billion), 2006-10
Table 100: Netherlands gdp (current prices, $ billion), 2006-10
Table 101: Netherlands inflation, 2006-10
Table 102: Netherlands consumer price index (absolute), 2006-10
Table 103: Netherlands exchange rate, 2006-10
Table 104: Spain generics market value: $ million, 2006-10
Table 105: Spain generics market volume: % of total pharma volume, 2006-10
Table 106: Spain generics market segmentation: % share, by value, 2010
Table 107: Spain generics market value forecast: $ million, 2010-15
Table 108: Spain generics market volume forecast: % of total pharma volume, 2010-15
Table 109: Spain size of population (million), 2006-10
Table 110: Spain gdp (constant 2000 prices, $ billion), 2006-10
Table 111: Spain gdp (current prices, $ billion), 2006-10
Table 112: Spain inflation, 2006-10
Table 113: Spain consumer price index (absolute), 2006-10
Table 114: Spain exchange rate, 2006-10
Table 115: United Kingdom generics market value: $ million, 2006-10
Table 116: United Kingdom generics market volume: % of total pharma volume, 2006-10
Table 117: United Kingdom generics market segmentation: % share, by value, 2010
Table 118: United Kingdom generics market value forecast: $ million, 2010-15
Table 119: United Kingdom generics market volume forecast: % of total pharma volume, 2010-15
Table 120: United Kingdom size of population (million), 2006-10
Table 121: United Kingdom gdp (constant 2000 prices, $ billion), 2006-10
Table 122: United Kingdom gdp (current prices, $ billion), 2006-10
Table 123: United Kingdom inflation, 2006-10
Table 124: United Kingdom consumer price index (absolute), 2006-10
Table 125: United Kingdom exchange rate, 2006-10
Table 126: United States generics market value: $ million, 2006-10
Table 127: United States generics market volume: % of total pharma volume, 2006-10
Table 128: United States generics market segmentation: % share, by value, 2010
Table 129: United States generics market value forecast: $ million, 2010-15
Table 130: United States generics market volume forecast: % of total pharma volume, 2010-15
Table 131: United States size of population (million), 2006-10
Table 132: United States gdp (constant 2000 prices, $ billion), 2006-10
Table 133: United States gdp (current prices, $ billion), 2006-10
Table 134: United States inflation, 2006-10
Table 135: United States consumer price index (absolute), 2006-10
Table 136: United States exchange rate, 2006-10
Table 137: Bayer AG: key facts
Table 138: Bayer AG: key financials ($)
Table 139: Bayer AG: key financials (€)
Table 140: Bayer AG: key financial ratios
Table 141: Mylan Inc: key facts
Table 142: Mylan Inc: key financials ($)
Table 143: Mylan Inc: key financial ratios
Table 144: Novartis AG: key facts
Table 145: Novartis AG: key financials ($)
Table 146: Novartis AG: key financial ratios
Table 147: Teva Pharmaceutical Industries Limited: key facts
Table 148: Teva Pharmaceutical Industries Limited: key financials ($)
Table 149: Teva Pharmaceutical Industries Limited: key financial ratios

LIST OF FIGURES

Figure 1: Global generics market value: $ million, 2006-10
Figure 2: Global generics market volume: % of total pharma volume, 2006-10
Figure 3: Global generics market segmentation: % share, by value, 2010
Figure 4: Forces driving competition in the global generics market, 2010
Figure 5: Drivers of buyer power in the global generics market, 2010
Figure 6: Drivers of supplier power in the global generics market, 2010
Figure 7: Factors influencing the likelihood of new entrants in the global generics market, 2010
Figure 8: Factors influencing the threat of substitutes in the global generics market, 2010
Figure 9: Drivers of degree of rivalry in the global generics market, 2010
Figure 10: Global generics market value forecast: $ million, 2010-15
Figure 11: Global generics market volume forecast: % of total pharma volume, 2010-15
Figure 12: Asia-Pacific generics market value: $ million, 2006-10
Figure 13: Asia-Pacific generics market volume: % of total pharma volume, 2006-10
Figure 14: Asia-Pacific generics market segmentation: % share, by value, 2010
Figure 15: Forces driving competition in the generics market in Asia-Pacific, 2010
Figure 16: Drivers of buyer power in the generics market in Asia-Pacific, 2010
Figure 17: Drivers of supplier power in the generics market in Asia-Pacific, 2010
Figure 18: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2010
Figure 19: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2010
Figure 20: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2010
Figure 21: Asia-Pacific generics market value forecast: $ million, 2010-15
Figure 22: Asia-Pacific generics market volume forecast: % of total pharma volume, 2010-15
Figure 23: Europe generics market value: $ million, 2006-10
Figure 24: Europe generics market volume: % of total pharma volume, 2006-10
Figure 25: Europe generics market segmentation: % share, by value, 2010
Figure 26: Forces driving competition in the generics market in Europe, 2010
Figure 27: Drivers of buyer power in the generics market in Europe, 2010
Figure 28: Drivers of supplier power in the generics market in Europe, 2010
Figure 29: Factors influencing the likelihood of new entrants in the generics market in Europe, 2010
Figure 30: Factors influencing the threat of substitutes in the generics market in Europe, 2010
Figure 31: Drivers of degree of rivalry in the generics market in Europe, 2010
Figure 32: Europe generics market value forecast: $ million, 2010-15
Figure 33: Europe generics market volume forecast: % of total pharma volume, 2010-15
Figure 34: France generics market value: $ million, 2006-10
Figure 35: France generics market volume: % of total pharma volume, 2006-10
Figure 36: France generics market segmentation: % share, by value, 2010
Figure 37: Forces driving competition in the generics market in France, 2010
Figure 38: Drivers of buyer power in the generics market in France, 2010
Figure 39: Drivers of supplier power in the generics market in France, 2010
Figure 40: Factors influencing the likelihood of new entrants in the generics market in France, 2010
Figure 41: Factors influencing the threat of substitutes in the generics market in France, 2010
Figure 42: Drivers of degree of rivalry in the generics market in France, 2010
Figure 43: France generics market value forecast: $ million, 2010-15
Figure 44: France generics market volume forecast: % of total pharma volume, 2010-15
Figure 45: Germany generics market value: $ million, 2006-10
Figure 46: Germany generics market volume: % of total pharma volume, 2006-10
Figure 47: Germany generics market segmentation: % share, by value, 2010
Figure 48: Forces driving competition in the generics market in Germany, 2010
Figure 49: Drivers of buyer power in the generics market in Germany, 2010
Figure 50: Drivers of supplier power in the generics market in Germany, 2010
Figure 51: Factors influencing the likelihood of new entrants in the generics market in Germany, 2010
Figure 52: Factors influencing the threat of substitutes in the generics market in Germany, 2010
Figure 53: Drivers of degree of rivalry in the generics market in Germany, 2010
Figure 54: Germany generics market value forecast: $ million, 2010-15
Figure 55: Germany generics market volume forecast: % of total pharma volume, 2010-15
Figure 56: Italy generics market value: $ million, 2006-10
Figure 57: Italy generics market volume: % of total pharma volume, 2006-10
Figure 58: Italy generics market segmentation: % share, by value, 2010
Figure 59: Forces driving competition in the generics market in Italy, 2010
Figure 60: Drivers of buyer power in the generics market in Italy, 2010
Figure 61: Drivers of supplier power in the generics market in Italy, 2010
Figure 62: Factors influencing the likelihood of new entrants in the generics market in Italy, 2010
Figure 63: Factors influencing the threat of substitutes in the generics market in Italy, 2010
Figure 64: Drivers of degree of rivalry in the generics market in Italy, 2010
Figure 65: Italy generics market value forecast: $ million, 2010-15
Figure 66: Italy generics market volume forecast: % of total pharma volume, 2010-15
Figure 67: Japan generics market value: $ million, 2006-10
Figure 68: Japan generics market volume: % of total pharma volume, 2006-10
Figure 69: Japan generics market segmentation: % share, by value, 2010
Figure 70: Forces driving competition in the generics market in Japan, 2010
Figure 71: Drivers of buyer power in the generics market in Japan, 2010
Figure 72: Drivers of supplier power in the generics market in Japan, 2010
Figure 73: Factors influencing the likelihood of new entrants in the generics market in Japan, 2010
Figure 74: Factors influencing the threat of substitutes in the generics market in Japan, 2010
Figure 75: Drivers of degree of rivalry in the generics market in Japan, 2010
Figure 76: Japan generics market value forecast: $ million, 2010-15
Figure 77: Japan generics market volume forecast: % of total pharma volume, 2010-15
Figure 78: Belgium generics market value: $ million, 2006-10
Figure 79: Belgium generics market volume: % of total pharma volume, 2006-10
Figure 80: Belgium generics market segmentation: % share, by value, 2010
Figure 81: Forces driving competition in the generics market in Belgium, 2010
Figure 82: Drivers of buyer power in the generics market in Belgium, 2010
Figure 83: Drivers of supplier power in the generics market in Belgium, 2010
Figure 84: Factors influencing the likelihood of new entrants in the generics market in Belgium, 2010
Figure 85: Factors influencing the threat of substitutes in the generics market in Belgium, 2010
Figure 86: Drivers of degree of rivalry in the generics market in Belgium, 2010
Figure 87: Belgium generics market value forecast: $ million, 2010-15
Figure 88: Belgium generics market volume forecast: % of total pharma volume, 2010-15
Figure 89: Canada generics market value: $ million, 2006-10
Figure 90: Canada generics market volume: % of total pharma volume, 2006-10
Figure 91: Canada generics market segmentation: % share, by value, 2010
Figure 92: Forces driving competition in the generics market in Canada, 2010
Figure 93: Drivers of buyer power in the generics market in Canada, 2010
Figure 94: Drivers of supplier power in the generics market in Canada, 2010
Figure 95: Factors influencing the likelihood of new entrants in the generics market in Canada, 2010
Figure 96: Factors influencing the threat of substitutes in the generics market in Canada, 2010
Figure 97: Drivers of degree of rivalry in the generics market in Canada, 2010
Figure 98: Canada generics market value forecast: $ million, 2010-15
Figure 99: Canada generics market volume forecast: % of total pharma volume, 2010-15
Figure 100: China generics market value: $ million, 2006-10
Figure 101: China generics market volume: % of total pharma volume, 2006-10
Figure 102: China generics market segmentation: % share, by value, 2010
Figure 103: Forces driving competition in the generics market in China, 2010
Figure 104: Drivers of buyer power in the generics market in China, 2010
Figure 105: Drivers of supplier power in the generics market in China, 2010
Figure 106: Factors influencing the likelihood of new entrants in the generics market in China, 2010
Figure 107: Factors influencing the threat of substitutes in the generics market in China, 2010
Figure 108: Drivers of degree of rivalry in the generics market in China, 2010
Figure 109: China generics market value forecast: $ million, 2010-15
Figure 110: China generics market volume forecast: % of total pharma volume, 2010-15
Figure 111: Netherlands generics market value: $ million, 2006-10
Figure 112: Netherlands generics market volume: % of total pharma volume, 2006-10
Figure 113: Netherlands generics market segmentation: % share, by value, 2010
Figure 114: Forces driving competition in the generics market in the Netherlands, 2010
Figure 115: Drivers of buyer power in the generics market in the Netherlands, 2010
Figure 116: Drivers of supplier power in the generics market in the Netherlands, 2010
Figure 117: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2010
Figure 118: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2010
Figure 119: Drivers of degree of rivalry in the generics market in the Netherlands, 2010
Figure 120: Netherlands generics market value forecast: $ million, 2010-15
Figure 121: Netherlands generics market volume forecast: % of total pharma volume, 2010-15
Figure 122: Spain generics market value: $ million, 2006-10
Figure 123: Spain generics market volume: % of total pharma volume, 2006-10
Figure 124: Spain generics market segmentation: % share, by value, 2010
Figure 125: Forces driving competition in the generics market in Spain, 2010
Figure 126: Drivers of buyer power in the generics market in Spain, 2010
Figure 127: Drivers of supplier power in the generics market in Spain, 2010
Figure 128: Factors influencing the likelihood of new entrants in the generics market in Spain, 2010
Figure 129: Factors influencing the threat of substitutes in the generics market in Spain, 2010
Figure 130: Drivers of degree of rivalry in the generics market in Spain, 2010
Figure 131: Spain generics market value forecast: $ million, 2010-15
Figure 132: Spain generics market volume forecast: % of total pharma volume, 2010-15
Figure 133: United Kingdom generics market value: $ million, 2006-10
Figure 134: United Kingdom generics market volume: % of total pharma volume, 2006-10
Figure 135: United Kingdom generics market segmentation: % share, by value, 2010
Figure 136: Forces driving competition in the generics market in the United Kingdom, 2010
Figure 137: Drivers of buyer power in the generics market in the United Kingdom, 2010
Figure 138: Drivers of supplier power in the generics market in the United Kingdom, 2010
Figure 139: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2010
Figure 140: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2010
Figure 141: Drivers of degree of rivalry in the generics market in the United Kingdom, 2010
Figure 142: United Kingdom generics market value forecast: $ million, 2010-15
Figure 143: United Kingdom generics market volume forecast: % of total pharma volume, 2010-15
Figure 144: United States generics market value: $ million, 2006-10
Figure 145: United States generics market volume: % of total pharma volume, 2006-10
Figure 146: United States generics market segmentation: % share, by value, 2010
Figure 147: Forces driving competition in the generics market in the United States, 2010
Figure 148: Drivers of buyer power in the generics market in the United States, 2010
Figure 149: Drivers of supplier power in the generics market in the United States, 2010
Figure 150: Factors influencing the likelihood of new entrants in the generics market in the United States, 2010
Figure 151: Factors influencing the threat of substitutes in the generics market in the United States, 2010
Figure 152: Drivers of degree of rivalry in the generics market in the United States, 2010
Figure 153: United States generics market value forecast: $ million, 2010-15
Figure 154: United States generics market volume forecast: % of total pharma volume, 2010-15
Figure 155: Bayer AG: revenues & profitability
Figure 156: Bayer AG: assets & liabilities
Figure 157: Mylan Inc: revenues & profitability
Figure 158: Mylan Inc: assets & liabilities
Figure 159: Novartis AG: revenues & profitability
Figure 160: Novartis AG: assets & liabilities
Figure 161: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 162: Teva Pharmaceutical Industries Limited: assets & liabilities

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

學名藥產業：全球產業指南

Generics: Global Industry Guide

簡介

目錄

目錄

關於DATAMONITOR

摘要整理

介紹

全球學名藥

亞太地區學名藥

歐洲學名藥

法國學名藥

德國學名藥

義大利學名藥

日本學名藥

比利時學名藥

加拿大學名藥

中國學名藥

荷蘭學名藥

西班牙學名藥

英國學名藥

美國學名藥

企業檔案分析

附錄

圖表

目錄

Abstract

Description